Trump Trade: Trump increasing medical marijuana, cannabidiol research

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.

MARIJUANA ORDER: President Donald Trump signed an Executive Order that will “improve medical marijuana and cannabidiol research to better inform patients and doctors,” the White House stated in a fact sheet. “The Order directs the Attorney General to expedite completion of the process of rescheduling marijuana to Schedule III of the Controlled Substance Act; The Order directs the White House Deputy Chief of Staff for Legislative, Political, and Public Affairs to work with the Congress to allow Americans to benefit from access to appropriate full-spectrum CBD products while still restricting the sale of products that pose serious health risks; The Order directs HHS to develop research methods and models utilizing real-world evidence to improve access to hemp-derived cannabinoid products in accordance with Federal law and to inform standards of care,” the White House fact sheet stated.

NOT LEGALIZATION: President Trump says marijuana executive order is “not legalization.” Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN) and Trulieve Cannabis (TCNNF).

U.S. LAUNCHES REVIEW: U.S. President Donald Trump’s administration has launched a review that may end with allowing Nvidia’s (NVDA) H200 chips to be shipped to China, Alexandra Alper of Reuters reports, citing five sources. Trump said earlier this month that he would allow the sales of the chips to China, with the U.S. collecting a 25% fee, believing the sales would help keep U.S. firms ahead of Chinese chipmakers by cutting demand in China. Questions remain over how quickly the U.S. may approve of the sales and whether Beijing would allow Chinese firms to purchase the chips.